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PAPER
Multidisciplinary rehabilitation for people with
Parkinson’s disease: a randomised controlled study
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Objective: To determine whether a programme of multidisciplinary rehabilitation and group support
achieves sustained benefit for people with Parkinson’s disease or their carers.
Methods: The study was a randomised controlled crossover trial comparing patients and carers who
had received rehabilitation four months before assessment with those who had not. Patients were
recruited from a neurology clinic, attended a day hospital from home weekly for six weeks using pri-
vate car or hospital transport, and received group educational activities and individual rehabilitation
from a multidisciplinary team. Patients were assessed at entry and at six months using a 25 item self
assessment Parkinson’s disease disability questionnaire, Euroqol-5d, SF-36, PDQ-39, hospital anxiety
and depression scale, and timed stand-walk-sit test. Carers were assessed using the carer strain index
and Euroqol-5d.
Results: 144 people with Parkinson’s disease without severe cognitive losses and able to travel to hos-
pital were registered (seven were duplicate registrations); 94 had assessments at baseline and six
months. Repeated measures analysis of variance comparing patients at the 24 week crossover point
showed that those receiving rehabilitation had a trend towards better stand-walk-sit score (p = 0.093)
and worse general and mental health (p = 0.002, p = 0.019). Carers of treated patients had a trend
towards more strain (p = 0.086). Analysis comparing patients before and six months after treatment
showed worsening in disability, quality of life, and carer strain.
Conclusions: Patients with Parkinson’s disease decline significantly over six months, but a short spell
of multidisciplinary rehabilitation may improve mobility. Follow up treatments may be needed to main-
tain any benefit.
Parkinson’s disease is a common cause of disability,especially in the elderly.1 2 Drug treatment is remarkablyeffective in the early stages but in most patients the
disease progresses so that they become increasingly disabled
despite optimal drug therapy.3 Furthermore there is some
reluctance to use drugs, both in the early stages and at doses
that fully reverse the impairments, because it is possible that
drugs themselves affect the progress or manifestations of the
disease.3 Surgical treatments are also available4 but carry risks
and anyway could not be used on the majority of patients.
Consequently there is a role for non-pharmacological
interventions,5–8 which should proceed in parallel with drug
treatment, especially as it has been found that the main
factors influencing quality of life are depression, disability,
postural instability, and cognitive decline.9
There have been several systematic reviews investigating
aspects of rehabilitation in patients with Parkinson’s disease,
but with one exception10 they conclude that there is no useful
evidence to support or refute any specific or general rehabili-
tation intervention.11–13 However, recent research does suggest
that multi-professional expert teams may offer effective and
efficient rehabilitation to patients with complex neurological
disability, whether acute14 or progressive.15 There is some
evidence that a specialist day hospital setting is an effective
way of delivering rehabilitation.16 17 Group occupational
therapy has been found to be effective for Parkinson’s disease
in one trial.18
We therefore set up a study to investigate the effectiveness
of a six week course of rehabilitation involving both individu-
alised treatments offered by a multidisciplinary team and
group educational support. The programme was delivered in a
day hospital setting to patients living in the community.
Analysis of data collected immediately after intervention was
completed has suggested some immediate benefit,19 but the
primary goal of this study was always to investigate the effects
four months after the end of intervention.
METHODS
We used a randomised, single blind controlled crossover
design comparing six weeks of active intervention with no
active intervention, assessing the outcome at six months after
entry. The actual design and flow of patients were influenced
by two factors: all patients had to be offered treatment, both
because the funding was primarily intended to deliver a serv-
ice and because team members wanted this; and access to
facilities was limited, such that only one group of six patients
could be treated at any one time. Therefore the control group
received the intervention six months after entry, immediately
after their second assessment, and both groups were
reassessed at one year.
Patients were recruited in cohorts of 12, randomised into
two groups of six with one receiving early and one delayed
intervention. As shown in fig 1, one cycle included 48 patients
and lasted 48 weeks. We aimed to recruit 144 patients in 12
cohorts, giving 24 separate treatment groups over three cycles
in three years.
The main analysis was a comparison of outcomes at 24
weeks, when one group of patients had received the
intervention—finishing about four months before—and the
other group was about to start treatment. To control for any
imbalance at entry, a repeated measures analysis of variance
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was undertaken20 using the SPSS general linear model
procedure.21 The effect of the intervention was tested by the
statistical interaction between treatment group and time. A
significant interaction would indicate that patients who had
received the intervention had fared differently from those who
had not. A second analysis using a similar procedure
compared data from all patients before rehabilitation and four
months after.
To be included, the following criteria had to be fulfilled: the
patients had to have Parkinson’s disease diagnosed clinically
by a consultant neurologist (PT) with a special interest in the
disease; they had to give their consent; there should be no
major cognitive losses (defined as scoring 7/10 or more on the
abbreviated mental test22); and they had to be able to attend
the day hospital using either their own or hospital transport.
After agreeing to participate they were accumulated into
cohorts of 12 patients and then randomised using a computer
generated block randomisation procedure giving two groups
of six. This was undertaken at an independent institution, and
the rehabilitation programme organiser was told the group for
each registered patient.
The assessments used were a Parkinson’s disease disability
questionnaire23; the Parkinson’s disease questionnaire (PDQ-
3924); the short form 36 item health survey (SF-36)25; the
Euroqol-5d (an index of health related quality of life)26; the
stand-walk-sit test,27 reported as seconds to complete test; the
nine hole peg test (NHPT) of manual dexterity, reported as
seconds to place all nine pegs28; the hospital anxiety and
depression scale (HADs29); and selected items concerning
speech from the unified Parkinson’s disease rating scale
(UPDRS).30. Carers were assessed using the carer strain
index31 and the Euroqol-5d.
The assessments were undertaken in the day hospital by an
independent assessor who was not involved in the treatment
programme and who was not informed of the patient’s group.
The same assessments were used at time zero (after random-
isation before any treatment), at 24 weeks (after one group
had received treatment but before the other group started
treatment), and at 48 weeks.
The intervention comprised a multidisciplinary rehabilita-
tion programme. The patient attended for whole days, coming
in once a week for six consecutive weeks. In the first week the
patient was assessed and an individualised programme of one
to one treatment was planned, to run over the next five weeks
from a specialist team including a Parkinson’s disease special-
ist nurse, a physiotherapist, a speech and language therapist,
and an occupational therapist. Each week the patient then
received two hours of individual treatment in the morning,
followed by group activities (for example, talks from experts
and relaxation) in the afternoon. All patients were assessed by
a social services care manager. The content of the programme
is available from the authors. After their last attendance each
patient was reassessed using a small battery of measures
reported elsewhere.19
RESULTS
In all, 137 separate patients were included, but there were 144
registrations because seven patients in the delayed treatment
group withdrew before treatment but then requested re-entry;
these were re-entered (and re-randomised) with a new
number. Of the 144 registrations, 124 (86%) were from a spe-
cialist Parkinson’s disease neurology clinic, nine from self
referral, four from geriatric clinics, and seven were re-
registrations. The flow the 144 registered patients is shown in
fig 2. The patients who withdrew and re-entered have only
been included once in any analysis.
Difficulties with transport and intercurrent illness led to
some patients missing one or more assessments or withdraw-
ing from the study. Consequently only 71 patients had all
three assessments, 94 had both a first and a second
assessment, and 86 had assessments both before and after
their allocated treatment spell.
Figure 1 Design of study; cycle 1 of three; flow of first 48 patients
over 48 weeks
Figure 2 Patient flow through the study.
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The baseline characteristics of the 94 patients and 68 carers
entered into the analysis are shown in table 1. The two groups
were similar on all variables, with no statistically significant
differences. The results on the samemeasures at the six month
crossover point are also shown in table 1. At this point the sec-
ond group was about to start treatment. There was only one
significant difference between the two groups—those patients
in the treated group who were able to walk on both occasions
were faster on the stand-walk-sit test (p = 0.044).
The results of general linear modelling analysis,20 21 allowing
for the initial patient state and the patient cohort, are shown
in column 5 of table 1. Significant differences were recorded
for SF-36 mental component summary scores and in the
SF-36 general health and mental health subscales: the treated
group had deteriorated while the control group had improved
at the crossover point. Similarly, the carers of treated patients
showed more strain, while the carers of patients about to start
rehabilitation showed less strain. Finally, patients in the
treated group showed a slight increase in speed in the stand-
walk-sit test, while the control group showed some deteriora-
tion.
A related measures t test was used to compare the data from
before treatment with the data from six months after the
treatment started in the 86 patients who had full pre- and
postintervention data (table 2). This showed that, despite
treatment, patients deteriorated significantly on some meas-
ures and showed no improvement, which is consistent with
the fact that Parkinson’s disease is a progressive disorder. A
statistically significant deterioration was recorded in four
measures: the Parkinson’s disease disability questionnaire,23
the SF-36 physical component summary, the SF-36 general
health subscale, and the Euroqol scale value. The carers also
showed more strain on the carer strain index.
Comparison of the 94 patients included in the primary
analysis with the remaining 43 patients (data not shown)
showed that the patients who did not complete the rehabilita-
tion programme and research protocol were more disabled
and older at baseline.
DISCUSSION
The main findings were a consistent worsening in all patient
measures, reaching statistical significance in their emotional
state and in carer stress over six months. This decline was
largely unaffected by rehabilitation, although there may have
been a minor, equivocal benefit on the mobility of walking
patients. This is in contrast to the data from the same patients
recorded immediately after intervention, which did show
beneficial effects.19 The study suffered from considerable loss
of patients but nonetheless it is one of the largest randomised
studies of non-pharmacological treatments for patients with
Parkinson’s disease, and it shows that such trials are feasible.
Onemajor weakness in the study is the loss of data from the
oldest and most disabled patients. However, the assessor was
independent of the treatment team, and was not aware of a
patient’s group when assessing a patient. It seems unlikely
that the loss of data has biased the results, and we believe that
Table 1 Comparison of early and late groups with full data from first and second assessments (n = 94)
Baseline 24 weeks
Significance*Early Late Early Late
Patients
n 53 41 53 41
Male:female (n) 30:23 26:15
Age (years) 71.3 (8.6) 70.4 (7.6)
PD disability questionnaire: 25 (good) to
125
48.9 (14.4) 50.3 (18.0) 53.4 (17.4) 55.3 (19.5) 0.558
PDQ-39: 0 (good) to 100 26.1 (11.3) 27.6 (12.2) 26.7 (13.7) 26.2 (13.2) 0.439
SF-36 physical component summary: 0
(bad) to 100
29.8 (10.8) 29.7 (9.7) 28.8 (10.9) 28.1 (11.8) 0.602
SF-36 mental component summary: 0 (bad)
to 100
50.6 (8.8) 48.0 (10.4) 49.8 (10.7) 51.2 (9.0) 0.037a
SF-36 mental health subscale: 0 (bad) to
100
71.1 (15.2) 67.6 (19.2) 67.9 (18.3) 72.5 (13.5) 0.019b
SF-36 general health subscale: 0 (bad) to
100
50.4 (21.5) 43.8 (17.4) 42.7 (18.7) 48.0 (17.6) 0.002c
Stand-walk-sit time (s) 20.1 (8.7), n=49 21.5 (8.0), n=39 19.4 (6.9), n=49 23.2 (10.3)d, n=39 0.093
Nine hole peg test (s) 23.9 (31.2), n=51 20.2 (7.4), n=41 20.4 (14.8),
n=52
20.0 (8.1), n=40 0.273
Euroqol scale: −0.59 (bad) to 1.00 0.73 (0.20) 0.74 (0.18) 0.66 (0.22) 0.67 (0.27) 0.951
Euroqol VAS: 0 (bad) to 100 72.7 (17.4) 71.4 (14.7) 68.2 (18.6) 68.7 (15.9) 0.633
UPDRS, speech: 0 (good) to 4 1.40 (0.97) 1.68 (0.93) 1.60 (0.97) 1.61 (0.97) 0.129
UPDRS, salivation: 0 (good) to 4 1.13 (1.11) 1.24 (1.04) 1.21 (1.03) 1.34 (1.17) 0.922
UPDRS, swallowing: 0 (good) to 4 0.89 (1.05) 0.85 (1.09) 1.15 (1.10) 1.10 (1.07) 0.923
UPDRS, writing: 0 (good) to 4 2.17 (1.14) 2.27 (1.16) 2.30 (1.15) 2.46 (1.05) 0.747
HAD, anxiety: 0 (good) to 21 6.1 (3.5) 6.2 (3.4) 6.1 (3.4) 5.8 (3.6) 0.472
HAD, depression: 0 (good) to 21 5.6 (3.9) 5.0 (3.6) 5.2 (3.3) 4.9 (3.2) 0.625
Carers (n = 68)
Carer strain index: 0 (no strain) to 13 3.0 (2.7), n=40 3.6 (3.4), n=28 3.7 (3.0), n=39 3.3 (3.0), n=28 0.086e
Euroqol scale: −0.59 (bad) to 1 0.86 (0.21), n=40 0.83 (0.33), n=27 0.82 (0.20),
n=39
0.81 (0.18), n=29 0.592
Euroqol VAS: 0 (bad) to 100 78.4 (17.1), n=40 79.0 (14.5), n=27 77.8 (19.8),
n=39
80.8 (14.5), n=29 0.996
Unless otherwise stated, values are mean (SD).
*Statistical significance of difference in change scores after use of general linear model analysis of variance.
aTreated group had deterioration in emotional distress and controls improved at 24 weeks relative to baseline.
bTreated group had deterioration in mental health and controls improved at 24 weeks relative to baseline.
cTreated group had deterioration in general health and controls improved at 24 weeks relative to baseline.
dTreated group significantly faster, p = 0.044 on direct comparison; p = 0.093 relative to baseline.
eCarers of treated group had increased strain and controls less strain at 24 weeks relative to baseline.
HAD, hospital anxiety and depression scale; PD, Parkinson’s disease; PDQ-39, Parkinson’s disease questionnaire; SF-36, short form 36; VAS, UPDRS,
unified Parkinson’s disease rating scale; visual analogue scale.
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the results are secure. Nevertheless, it will have reduced the
power of the study, and it is possible that some significant
effects have been missed. Moreover, the crossover design may
have led to some bias against treatment. At the crossover point
the patients in the treated group were not only 18 weeks away
from treatment, but they were also aware that no more treat-
ment would be available. Given that they had experienced
benefit themselves after treatment,19 they may have been feel-
ing depressed. In addition it is possible that attendance and
the educational package may have increased their awareness
of future deterioration, causing some distress. In contrast the
control group patients were about to start treatment, which
may have improved their mood. This might be the explanation
for the consistent changes in mood and carer strain found.
Our study gives useful information on the measurement of
disability in trials investigating Parkinson’s disease. The
assessments used were all practical, and some measures did
detect the expected deterioration over 24 weeks, particularly
the Parkinson’s disease disability measure,23 which has also
been found to be sensitive to rehabilitation input in another
trial of rehabilitation in Parkinson’s disease.32 The stand-walk-
sit test, the carer strain index, the SF-36, and the Euroqol also
seemed sensitive to change, whereas the PDQ-39 did not. This
study not only provides data that will allow others to make
more accurate power calculations but also suggests that these
measures (or an equivalent timed measure of mobility) might
be the best measures to use.
One notable finding of this study is the consistent decline in
almost all measures over the six month period. This was of
similar size in both the treated and untreated patients, and
mirrors the gradual decline also found in stroke patients later
after stroke.33
In contrast to the uniform decline in function, the minor
differences in change of function detected are difficult to
evaluate and may simply arise through chance. However, the
intervention may have improved mobility and this is worth
investigating further because a similar small input was found
to improve mobility late after stroke.33 The effect on the
patient’s emotional state and perception of health and carer
strain is also difficult to evaluate because, as stated above, it is
possible that at the crossover point the control group patients
were feeling better precisely because they were about to start
the programme, whereas the patients who had already had
the intervention were depressed because no further input was
going to happen.
Why was little evidence of benefit found? The fact that the
patients were largely recruited from a specialist neurological
clinic might mean that they were already well managed, and
had received other professional support, and that there was
only a limited scope for further improvement. Second, it might
be argued that six days of rehabilitation totalling about 10
hours of face to face treatment and 10 hours of group therapy
was too little to expect to find effects 18 weeks after stopping
it. Third, the team did not include a clinical psychologist or a
doctor, but the specialist nurse did refer patients back to the
neurologist if necessary. Fourth, the immediate assessment of
patients after the programme showed significant improve-
ment across a range of measures and high participant
satisfaction19 and therefore it is possible that patients need
repeated input to sustain early improvement in the face of a
progressive deterioration. Fifth, the measures may either have
failed to assess domains where major benefits were occurring,
or may have been insensitive to clinically significant change.
Our finding of a decline in most measures over six months is
consistent with the known progress of the disease and
suggests that the measures were adequately sensitive to
change even though some measures such as the UPDRS sub-
scales were weak.Our measures cover all activity domains that
seem to be relevant. Last, the study may have been too small to
detect a benefit.
Conclusions
Several conclusions can be drawn. First, the design and meas-
ures used were practical, and consequently we have shown
that it is possible to undertake research into multi-
professional rehabilitation in patients with Parkinson’s
disease in a district general hospital. Second, we have given an
estimate both of the variance in outcome data and of the likely
Table 2 Comparison of 86 patients before treatment and 24 weeks later
Group Before After Significance*
Patients (n=86)
Male:female (n) 50:36 50:36
Age (years) 71.3 (8.6)
PD disability questionnaire 51.7 (17.6) 54.8 (18.9) 0.031a
PDQ-39 25.5 (10.7) 26.0 (12.7) 0.687
SF-36 physical component summary 29.5 (11.1) 27.28 (10.9) 0.046a
SF-36 mental component summary 51.0 (8.4) 50.5 (10.3) 0.655
SF-36 mental health subscale 71.5 (13.5) 70.3 (17.2) 0.474
SF-36 general health subscale 50.3 (21.0) 38.65 (19.5) <0.001a
Euroqol scale 0.72 (0.22) 0.66 (0.21) 0.026a
Euroqol VAS 71.9 (16.4) 68.2 (19.4) 0.110
Stand-walk-sit test (s) 22.9 (18.2), n=82 22.2 (13.5), n=83 0.752
Nine hole peg test seconds 22.4 (24.8), n=83 20.7 (13.0), n=83 0.313
UPRS, speech 1.42 (0.96) 1.51 (0.95) 0.380
UPRS, salivation 1.27 (1.22) 1.36 (1.10) 0.369
UPRS, swallowing 0.91 (1.05) 0.97 (1.05) 0.607
UPRS, writing 2.29 (1.16) 2.38 (1.12) 0.729
HAD, anxiety 6.0 (3.4) 5.8 (3.21) 0.729
HAD, depression 5.2 (3.6) 5.0 (3.2) 0.638
Carers (n=63)
Carer strain index 3.1 (2.7), n=61 3.8 (3.2), n=62 0.045a
Euroqol scale 0.82 (0.22) 0.79 (0.24) 0.235
Euroqol VAS 78.0 (16.6) 77.5 (19.5) 0.873
Unless otherwise stated, values are mean (SD).
*p value of paired t test.
aPatients or carers worse at 24 weeks, after treatment, on these measures.
HAD, hospital anxiety and depression scale; PD, Parkinson’s disease; PDQ-39, Parkinson’s disease
questionnaire; SF-36, short form 36; UPDRS, unified Parkinson’s disease rating scale; VAS, visual analogue
scale.
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loss of patients in such studies. Third, this study neither sup-
ports individual rehabilitation combined with group therapy
nor does it show it to be ineffective. The particular
circumstances—with patients coming from a specialist clinic
and the lack of follow up rehabilitation—may have made it
difficult to show sustained benefit. Fourth, we believe that
future studies should investigate from a clinical and economic
perspective both the content of rehabilitation, especially the
involvement of clinical psychologists, and also varying
patterns of delivery (for example, regular follow up and a
more local, more prolonged, but less frequent programme of
rehabilitation). Last, future studies could reduce the range of
assessments used to a subset of those used in this study.
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